AbCellera Biologics Inc. (ABCL)
Automate Your Wheel Strategy on ABCL
With Tiblio's Option Bot, you can configure your own wheel strategy including ABCL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABCL
- Rev/Share 0.1101
- Book/Share 3.3737
- PB 1.285
- Debt/Equity 0.1411
- CurrentRatio 11.073
- ROIC -0.199
- MktCap 1295530705.0
- FreeCF/Share -0.4656
- PFCF -9.3212
- PE -7.8117
- Debt/Assets 0.1013
- DivYield 0
- ROE -0.1591
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ABCL | Leerink Partners | -- | Outperform | -- | $5 | July 7, 2025 |
| Downgrade | ABCL | The Benchmark Company | Buy | Hold | -- | -- | Aug. 20, 2024 |
News
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
ABCELLERA BIOLG (ABCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
Published: June 02, 2025 by: The Motley Fool
Sentiment: Positive
Investors were surely discovering drug discovery company AbCellera Biologics (ABCL 6.19%) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by almost 6% on the day.
Read More
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
Published: May 30, 2025 by: Business Wire
Sentiment: Neutral
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575.
Read More
AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Jacqueline Kisa - TD Securities Puneet Souda - Leerink Partners LLC Malcolm Hoffman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Good afternoon, and welcome to AbCellera's First Quarter 2025 Business Update and Conference Call. My name is Jasmine, and I will facilitate the audio portion of today's interactive broadcast.
Read More
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.
Read More
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Steve Dechert - KeyBanc Jacqueline Kisa - TD Securities Malcolm Hoffman - BMO Capital Markets Operator Good afternoon and welcome to AbCellera's Full Year 2024 Business Update Conference Call. My name is Tamia [ph] and I will facilitate the audio portion of today's interactive broadcast.
Read More
About AbCellera Biologics Inc. (ABCL)
- IPO Date 2020-12-11
- Website https://www.abcellera.com
- Industry Biotechnology
- CEO Carl L.G. Hansen
- Employees 596